SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Summer Interns

IP-Watch interns talk about their Geneva experience in summer 2013. 2:42.

Inside Views

Submit ideas to info [at] ip-watch [dot] ch!

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Internet Governance And Celestial Mechanics

At a recent meeting of the UN Commission on Science and Technology for Development (CSTD), a Cuban expert offered a humorous – but at the same time serious – vision of global internet governance. Below are his remarks.


Latest Comments
  • CALLING FOR UPOV -2014 TO ADDRESS AFRICAN FARMERS... »
  • One can expect significant opposition to the proop... »

  • For IPW Subscribers

    A directory of IP delegates in Geneva. Read more>

    A guide to Geneva-based public health and intellectual property organisations. Read More >


    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >

    WHO Enters Next Phase Of Global Plan To Increase Flu Vaccine Production

    Published on 14 July 2011 @ 6:04 pm

    By , Intellectual Property Watch

    The World Health Organization will be entering a new phase of its global action plan for influenza vaccines, a WHO representative told reporters today. The goals of the first phase of the programme should be furthered but with more attention given to the local health and policy environment, WHO said.

    The WHO held its first review of its Global Action Plan for Influenza Vaccines (GAP) on 12-14 July. GAP was developed in 2006 by WHO, public health and academic experts, vaccine manufacturers and funding agencies from developed and developing countries, according to the WHO.

    WHO Assistant Director-General for Innovation, Information, Evidence and Research Marie-Paule Kieny, said at a press conference today that GAP had been put together in 2006 in response to worries from the international community about the gap between demand and supply of flu pandemic vaccines. The project is so designated as “GAP 1.”

    The increase in capacity of seasonal flu vaccine production is considered as a prerequisite for the world to be able to produce sufficient vaccine in the event of a global pandemic.

    Significant success has been noted since the start of the action plan, she said, in particular in surveillance and understanding of epidemiological patterns for influenza, in developed and in developing countries. GAP 1 has been a catalyst in the significant expansion of global flu vaccine manufacturing capacity, she said. The past five years have also seen a change in the landscape of vaccine production, with 11 additional developing country manufacturers. Research and development has also progressed in antigen production methods, she said.

    GAP 1 was constructed around three pillars, Kieny said: an increase in seasonal vaccine use to combat seasonal influenza, driving the market and increasing production capacity; an increase in vaccine production capacity both in developed and in developing countries; and an increase in the efforts of research and development for better vaccines with broader spectrum.

    This week’s meeting launched the second phase of the action plan, she said.

    According to the Chair of the GAP Advisory Group, Pathom Sawanpanyalert, director of the Center for International Cooperation and National Institute of Health, Nonthaburi, Thailand, the three objectives of GAP1 will be furthered and influenza vaccine will be used as a tool to combat influenza pandemics, not to increase profit, he said. More information is needed to assess the influenza situation, he said. In some economies, the information is not available for various reasons, one of which is that some countries do not include influenza in their immunization campaigns. However, influenza vaccines have improved the health of people, he said.

    The next step is to consider influenza vaccine in the context of the different parts of the world, with different needs and different policies, Sawanpanyalert said.

    The WHO Chair of the International Health Regulations Review Committee, Harvey Fineberg, president of the Washington DC-based Institute of Medicine, said the review showed that the world is still ill-prepared for a major pandemic, “in good measure because we do not have the capacity in a timely manner to produce sufficient vaccines to protect the world’s population.”

    GAP 1 “has been one of the bright spots” in the success of WHO in the last five years, he said, considering the situation of vaccines production capacity in 2006.

    The WHO had come under criticism in 2009 after declaring a world pandemic and the pandemic proved to be a modest outbreak, which looked like it had acted to the advantage of the pharmaceutical industry. A WHO review committee exonerated the WHO [pdf] from malfeasance and gave a set of recommendations (IPW, WHO, 29 March 2011).

    More successful and intensive communication to the public and professionals is needed, Fineberg said, to engage them in the decision-making in a constructive way. Additional research is also needed as is a focus on the delivery, distribution and use of vaccines.

    GAP and the Pandemic Preparedness Framework

    To a question about the relationship between GAP 2 and the newly adopted Pandemic Influenza Preparedness (PIP) framework [pdf] for the sharing of influenza viruses and access to vaccines and other benefits, Fineberg said that the PIP framework involves two basic elements: the sharing of the virus, and the availability of vaccines. The PIP framework “ is not so much concerned with the total production capacity of vaccines as it is focused on distribution of either fixed amount or fixed proportion of production to a pool that can be redistributed by WHO where it is most needed,” he said.

    “PIP deals with the availability of a portion of the world’s production for use in countries in which otherwise we do not have access to vaccines, and GAP deals with improving the world capacity to produce, distribute and have available sufficient amounts of vaccines,” Fineberg added. “In that sense the two work in a highly complementary fashion,” he said.

    The WHO estimate of the seasonal flu vaccine manufacturing capacities is 800,000 million doses per year, compared to 350,000 in 2006, Kieny said. The estimate rises to 1.7 billion doses by 2015 if all the projects going on now are successful, she said.

    There are currently 37 manufacturers of influenza vaccine in the world, either operating now or operational by 2015 Kieny said. According to a WHO document, 10 manufacturers are in Europe, 14 in the Western Pacific region, 6 in the South East Asia region, and 5 in the Americas region. Included in the 37 are 11 new manufacturers in 11 low or middle-income countries are part of the GAP programme, she said. Those countries have been working with WHO to acquire technologies to produce influenza vaccine, she said.

    The documents from the meeting should be posted on the WHO website early next week, according to WHO officials.

    Catherine Saez may be reached at info@ip-watch.ch.

     

    Comments

    1. Flus.us » Blog Archive » WHO touts flu, pandemic vax readiness » Flus.us says:

      [...] see the story- here’s more- read the U.S. vax investment [...]


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

     

     
    Your IP address is 54.83.239.145